Bioequivalence Study of TNX-102 SL 2.8 mg Sublingual Tablets From Two Manufacturers.
NCT03168022
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Healthy Adults
Interventions
DRUG:
Treatment A
DRUG:
Treatment B
Sponsor
Tonix Pharmaceuticals, Inc.